Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies (Q90350008)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31564196%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

title

Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31564196%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

author name string

Yining Zhao

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31564196%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Yumei Li

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31564196%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Xiaoqiong Wu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31564196%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Li Li

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31564196%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Jiayu Liu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31564196%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Yanlan Wang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31564196%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Yue Liu

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31564196%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Qing Li

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31564196%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Zhong Wang

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31564196%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

publication date

29 September 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31564196%20AND%20SRC:MED&resulttype=core&format=json

Cancer Biology and Therapy

13 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31564196%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31564196%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31564196%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

page(s)

72-80

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31564196%20AND%20SRC:MED&resulttype=core&format=json

Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence

13 April 2020

cites work

1 reference

12 December 2020

Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments

1 reference

12 December 2020

Naturally occurring antibodies devoid of light chains

1 reference

12 December 2020

Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group

1 reference

12 December 2020

Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype

1 reference

12 December 2020

The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues

1 reference

12 December 2020

Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity

1 reference

12 December 2020

A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors.

1 reference

12 December 2020

Immunotherapeutic perspective for bispecific antibodies

1 reference

12 December 2020

Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity

1 reference

12 December 2020

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

12 December 2020

Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.

1 reference

12 December 2020

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

1 reference

12 December 2020

Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.

1 reference

12 December 2020

Isolation, characterization and pentamerization of alpha-cobrotoxin specific single-domain antibodies from a naïve phage display library: preliminary findings for antivenom development

1 reference

12 December 2020

Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells

1 reference

12 December 2020

Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans

1 reference

12 December 2020

Camelid immunoglobulins and nanobody technology.

1 reference

12 December 2020

Radionuclide-Based Cancer Imaging Targeting the Carcinoembryonic Antigen.

1 reference

12 December 2020

Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity

1 reference

12 December 2020

Rituximab in immunologic glomerular diseases

1 reference

12 December 2020

The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA

1 reference

12 December 2020

Generation of single domain antibody fragments derived from camelids and generation of manifold constructs

1 reference

12 December 2020

Development of oligoclonal nanobodies for targeting the tumor-associated glycoprotein 72 antigen

1 reference

12 December 2020

Nanobodies: natural single-domain antibodies

1 reference

12 December 2020

Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells

1 reference

12 December 2020

Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy

1 reference

12 December 2020

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells

1 reference

12 December 2020

Exploitation of rolling circle amplification for the construction of large phage-display antibody libraries

1 reference

12 December 2020

Blinatumomab for the treatment of B-cell lymphoma.

1 reference

12 December 2020

Increasing the potency of neutralizing single-domain antibodies by functionalization with a CD11b/CD18 binding domain.

1 reference

12 December 2020

A novel bispecific antibody, S-Fab, induces potent cancer cell killing

1 reference

12 December 2020

Bispecific antibodies and their applications

1 reference

12 December 2020

A novel bispecific antibody, BiSS, with potent anti-cancer activities

1 reference

12 December 2020

Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity

1 reference

12 December 2020

Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers.

1 reference

12 December 2020

Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells.

1 reference

12 December 2020

Redirected T Cell Cytotoxicity in Cancer Therapy

1 reference

12 December 2020